UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2052-17
Program Prior Authorization/Medical Necessity
Medication Harvoni® (ledipasvir/sofosbuvir)
P&T Approval Date 4/2015, 8/2015, 11/2015, 8/2016, 12/2016, 9/2017, 11/2017, 6/2019,
3/2020, 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Harvoni® (ledipasvir/sofosbuvir) is a fixed-dose combination of ledipasvir, a hepatitis C virus
(HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor,
and is indicated for the treatment of chronic HCV in adults and pediatric patients 3 years of age
and older:
• Genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
• Genotype 1 infection with decompensated cirrhosis, in combination with ribavirin
• Genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with
compensated cirrhosis, in combination with ribavirin.
2. Coverage Criteriaa:
A. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve patients
without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL, Harvoni will
be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
2. Patient is treatment-naive [patient has not experienced treatment failure (defined as viral
relapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon
plus ribavirin or peginterferon plus ribavirin plus an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-AND-
3. Submission of laboratory report documenting a pre-treatment HCV RNA less than 6
million IU/mL
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
© 2025 UnitedHealthcare Services, Inc.
1
agent [e.g., Sovaldi (sofosbuvir)]
Authorization will be issued for 8 weeks.
B. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve patients who
are without cirrhosis and have a pre-treatment HCV RNA equal to or greater than 6 million
IU/mL OR have compensated cirrhosis regardless of pre-treatment HCV RNA level, Harvoni
will be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
2. Patient is treatment-naive [patient has not experienced treatment failure (defined as viral
relapse, breakthrough while on therapy, or non-responder to therapy) with peginterferon
plus ribavirin or peginterferon plus ribavirin plus an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-AND-
3. One of the following:
a. Both of the following:
i. Patient is without cirrhosis
-AND-
ii. Submission of laboratory report documenting a pre-treatment HCV RNA equal to
or greater than 6 million IU/mL
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
6. One of the following:
© 2025 UnitedHealthcare Services, Inc.
2
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 12 weeks.
C. For the treatment of chronic hepatitis C genotype 1 infection in treatment-naïve OR treatment-
experienced patients with decompensated cirrhosis, Harvoni will be approved based on all of
the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
2. One of the following:
a. Patient is treatment-naive [patient has not experienced treatment failure (defined as
viral relapse, breakthrough while on therapy, or non-responder to therapy) with
peginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease
inhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-OR-
b. Patient has experienced treatment failure, defined as viral relapse/breakthrough while
on therapy or non-responder to therapy, with a previous treatment regimen that
included peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)
-AND-
3. Both of the following:
a. Patient has decompensated liver disease (Child-Pugh B or C)
-AND-
b. Used in combination with ribavirin
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
© 2025 UnitedHealthcare Services, Inc.
3
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
6. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 12 weeks.
D. For the treatment of chronic hepatitis C genotype 1 infection in treatment-experienced patients
without cirrhosis, Harvoni will be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
2. Patient has experienced treatment failure, defined as viral relapse/breakthrough while on
therapy or non-responder to therapy, with a previous treatment regimen that included
peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek, Olysio, Victrelis)
plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)
-AND-
3. Patient is without cirrhosis
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
6. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
© 2025 UnitedHealthcare Services, Inc.
4
Authorization will be issued for 12 weeks.
E. For the treatment of chronic hepatitis C genotype 1 infection in treatment-experienced patients
with compensated cirrhosis, Harvoni will be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 infection
-AND-
2. Patient has experienced treatment failure, defined as viral relapse/breakthrough while on
therapy or non-responder to therapy, with a previous treatment regimen that included
peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek, Olysio, Victrelis)
plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)
-AND-
3. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
4. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
5. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
6. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 24 weeks.
F. For the treatment of chronic hepatitis C genotype 1 or 4 infection in treatment-naïve and
treatment-experienced liver transplant recipients who are without cirrhosis or have
compensated cirrhosis, Harvoni will be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1 or 4 infection
© 2025 UnitedHealthcare Services, Inc.
5
-AND-
2. One of the following:
a. Patient is treatment-naive [patient has not experienced treatment failure (defined as
viral relapse, breakthrough while on therapy, or non-responder to therapy) with
peginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease
inhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-OR-
b. Patient has experienced treatment failure, defined as viral relapse/breakthrough while
on therapy or non-responder to therapy, with a previous treatment regimen that
included peginterferon plus ribavirin or an HCV protease inhibitor (e.g., Incivek,
Olysio, Victrelis) plus peginterferon plus ribavirin or Sovaldi (sofosbuvir)
-AND-
3. Both of the following:
a. Patient has received a liver transplant
-AND-
b. Used in combination with ribavirin
-AND-
4. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
5. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
6. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
© 2025 UnitedHealthcare Services, Inc.
6
7. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 12 weeks.
G. For the treatment of chronic hepatitis C genotype 4, 5 or 6 infection in treatment-naïve or
treatment-experienced patients who are without cirrhosis or have compensated cirrhosis,
Harvoni will be approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 4, 5 or 6 infection
-AND-
2. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
3. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
4. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
5. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 12 weeks.
© 2025 UnitedHealthcare Services, Inc.
7
H. For the treatment of chronic hepatitis C genotype 1, 4, 5, or 6 infection in treatment-naïve and
non-direct acting antiviral treatment-experienced kidney transplant recipients who are without
cirrhosis or have compensated cirrhosis, Harvoni will be approved based on all of the
following criteria:
1. Diagnosis of chronic hepatitis C genotype 1, 4, 5, or 6 infection
-AND-
2. One of the following:
a. Patient is treatment-naive [patient has not experienced treatment failure (defined as
viral relapse, breakthrough while on therapy, or nonresponder to therapy) with
peginterferon plus ribavirin or peginterferon plus ribavirin plus an HCV protease
inhibitor (e.g., Incivek, Olysio, Victrelis) or Sovaldi (sofosbuvir)]
-OR-
b. Patient has not been previously treated with a direct acting antiviral [e.g., Sovaldi
(sofosbuvir)]
-AND-
3. Patient has received a kidney transplant
-AND-
4. One of the following:
a. Patient is without cirrhosis
-OR-
b. Patient has compensated cirrhosis (Child-Pugh A)
-AND-
5. Physician/provider asserts patient demonstrates treatment readiness, including the ability
to adhere to the treatment regimen
-AND-
6. Patient is not receiving Harvoni in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
© 2025 UnitedHealthcare Services, Inc.
8
-AND-
7. One of the following:
a. History of intolerance or contraindication to Epclusa therapy
-OR-
b. Patient is currently on Harvoni therapy
Authorization will be issued for 12 weeks.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply Limits may be in place.
4. References:
1. Harvoni [package insert]. Foster City, CA: Gilead Sciences, Inc.; December 2024.
2. American Association for the Study of Liver Diseases and the Infectious Diseases Society of
America. Recommendations for Testing, Managing, and Treating Hepatitis C.
http://www.hcvguidelines.org/full-report-view. Accessed April 9, 2025.
Program Prior Authorization/Medical Necessity - Harvoni (ledipasvir/sofosbuvir)
Change Control
4/2015 Coverage requirements for State of New Jersey effective 5/18/2015.
8/2015 Added criteria for genotype 4 infection
11/2015 Changed program title to include all lines of business, added genotypes 5
and 6, and updated language regarding documentation of liver fibrosis.
8/2016 Revised treatment-experienced with cirrhosis criteria to include ribavirin
and Epclusa.
11/2016 Added California coverage information.
12/2016 Removed abstinence-based criteria and replaced with treatment readiness
screening criteria. Added Maryland, Indiana and West Virginia coverage
information.
5/2017 Administrative update to reorder criteria. State mandate reference
language updated.
5/2017 Administrative update to correct formatting.
9/2017 Revised step therapy criteria based on new product availability, included
NY prescriber requirement, removed treatment readiness screening tools
and removed medical record submission requirements.
© 2025 UnitedHealthcare Services, Inc.
9
11/2017 Update to language in Genotype 1 criteria for treatment naïve
compensated cirrhotic patients.
6/2019 Annual review. Added kidney transplant recipient section based on
AASLD guidelines to allow for 12 weeks of therapy. Updated references.
3/2020 Added requirement of Epclusa use for requests greater than 8 weeks.
Clarified kidney transplant criteria to align with current AASLD
guidelines. Updated background and references.
5/2021 Annual review. Removed prescriber requirement. Updated references.
5/2022 Reformatted criteria. Updated references.
5/2023 Annual review. Updated references.
5/2024 Annual review. Removed liver disease staging criteria that was included
for quality purposes rather than part of coverage decision. Updated
references.
5/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
10